Transarterial Chemoembolization (TACE) Market is Growing at a Promising CAGR of 8.57% During Forecast 2019-2025


Market Forecast:
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs mainly due to chronic liver disease and cirrhosis. It is the third leading cause of cancer deaths worldwide, with over 500,000 people affected. Transarterial chemoembolization is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC.
The global Transarterial Chemoembolization (TACE) Market Is expected to exhibit a CAGR of 8.57% to reach USD 2777.22 billion by 2025.
Market Influencer:
Improvement in the reimbursement scenario and increasing incidence of HCC are impacting the growth of the market. HCC accounts for approximately 70% to 90% of all primary liver cancers and is the third most fatal cancer worldwide. Moreover, Lipiodol is approved for National Health Insurance reimbursement for transcatheter arterial chemoembolization for HCC.
Key Players:
·         Advaxis Inc
·         Baxter
·         Bellicum Pharmaceuticals, Inc
·         Boston Scientific Corporation
·         Cook
·         Hikma Pharmaceuticals PLC
·         Isofol Medical AB
·         Nippon Kayaku Co
·         Novartis
·         Sirtex SIR-Spheres Pty Ltd
·         Spectrum Pharmaceuticals
·         Jiangsu Hengrui Medicine Co
Regional Analysis:
Americas: The largest regional market for transarterial chemoembolization, the Americas has a well-established healthcare industry, with the increasing preference for early diagnosis. Increased R&D funding is also propelling the Americas market growth in the region.
North America: The North American market is divided into the US and Canada.
US: The larger market in North America. Healthcare expenditure in the US was over USD 3.65 trillion in 2018. Moreover, increasing awareness about HCC and early diagnosis are also boosting the transarterial chemoembolization market in this country. The American Association for the Study of Liver Diseases thus recommends hepatic imaging every six months among patients at risk for HCC
Europe: Rising healthcare expenditure is one of the key drivers in Europe transarterial chemoembolization (TACE) market. The European Commission (EC) reported that in 2017, the total government expenditure in the European Union (EU) accounted to 45.8% of the gross domestic product (GDP) and government expenditure on health as a proportion of GDP was 7.0%
Asia-Pacific: The fastest-growing regional market for Transarterial chemoembolization due to the increasing incidence of HCC in this region.
The vast majority of cases have been observed in Asian countries. China alone representing half of the worldwide cases. In Asia, 70-80% of all hepatocellular carcinoma is attributable to hepatitis B virus, with the notable exception of Japan, where hepatitis C is the main factor
Japan: Japan held the largest revenue share in the Asia-pacific region in 2018 due to presence of better reimbursement policies. For instance, in November 2013, Guerbet Japan announced that Lipiodol is approved for National Health Insurance reimbursement for Transcatheter Arterial Chemoembolization (TACE) for HCC
Middle East & Africa: Limited medical infrastructure limits the size of the regional transarterial chemoembolization market. However, the presence of favorable government initiatives is expected to fuel the growth of the market during the forecast period.





Comments

Post a Comment

Popular posts from this blog

Proteomics Market Analysis, Demand Overview, Growth Analysis, Current Trends, Updates, and Global Industry Forecast to 2023

Market Highlights: The global proteomics market is anticipated to hold a market value of USD 23.2 billion in the year 2017 and is expected to grow at a CAGR of 14.1% during the forecast period. Proteomics is a science which is used to estimate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. Also, it has extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis. Increasing need for personalized medicine, R&D expenditure, technological advancements and increased funding for proteomics project are expected to drive the market growth over the forecast period. For instance, in July 2017, Biognosys AG received USD 5 million funding from its new as well as existing investors. These new funds will be used for extending commercial operations and also to accelerate the development of next generation prote...
Read more

Pancreatic Cancer Market: America to Command the Largest Share

Market Overview: Pancreatic cancer can be defined as an enlarged tumor, which is generally caused by malignant cells present in the tissues of the pancreas. This type of cancer is generally caused due to drinking alcohol, smoking, genetic factors, radiotherapy in the past, obesity, inflammation of the pancreas, and diabetes mellitus. It is a type of cancer that starts in the pancreas and is a highly lethal disease. The global Pancreatic Cancer Market , as per a report by Market Research Future (MRFR) is touted to register 8.1% CAGR during the forecast period ( 2017-2023 ). The dearth of therapeutic approaches for early-stage detection has resulted in increased incidences of pancreatic cancer. Soaring prevalence of pancreatic cancer has resulted in germline mutations, thereby causing the defective genes to pass down to the children from their parents, thus making early detection of pancreatic cancer important. This has led to the growth of the market across the globe. Surging dem...
Read more

Immune Thrombocytopenia (ITP) Market is Estimated to Record Promising CAGR of 5.78% During Forecast 2018-2023

Market Highlights: As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers. ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ...
Read more